25 Posts Not To Miss From SABCS 2023
The San Antonio Breast Cancer Symposium 2023 (SABCS 2023) took place in San Antonio, Texas in USA from 5th to 9th December. Our team at OncoDaily has handpicked 25 posts SABCS 2023 that you shouldn’t miss.
Jason Mouabbi (USA)
“Big shoutout to the organizing committee of SABCS23. Thank you for actively listening to the Invasive lobular carcinoma (ILC) community’s voice and incorporating a dedicated ILC session this year. Your responsiveness is a testament to the commitment to inclusivity and collaboration in advancing breast cancer research.”
Stephanie Graff (USA)
“On 6th line therapy for Metastatic breast cancer (MBC), Abigail Johnston has faced 193 treatment decisions. From lines of therapy to side effect medications. Clinicians should:
- Ask about what is important to our patient
- How they make decisions
- How they best learn”
Erika Hamilton (USA)
“Nicholas Turner presents monarchE correlative data from WES and RNA
- 80% luminal A/B, ~75% oncotype high
- Benefit of abema across intrinsic subtypes
- Abema benefitted from increase and decrease of oncotype
- Benefit regardless of PI3, CCND1, maybe not among those MYC amplified”
Paolo Tarantino (USA)
“Targeted therapies, Immuno-oncology and Antibody Drug Conjugates (ADCs) have really shortened the distance between tumor types, with agnostic approvals and cross-histology insights. Awesome to catch up with precision medicine king, Vivek Subbiah between the SABCS23 corridors!”
Yara Abdou (USA)
“NATALEE update: we continue to see Invasive disease-free survival (iDFS) improvement with adjuvant Ribociclib (absolute increase of 3.1% at 3 years) although less pronounced in low risk groups. Absolute Distant disease-free survival (DDFS) of 2.7%. 78% of patients no longer on Ribociclib at this time point.”
Emily Podany (USA)
“I am so honored to have received an American Association for Cancer Research (AACR) Scholar-in-Training Award for the work on ctDNA that I’m presenting at SABCS 2023 at tomorrow morning’s Poster Spotlight Session. Thank you so much to the AACR and to Washington University School of Medicine.”
Jennifer Litton (USA)
“Mariana Chavez-MacGregor’s overview of the year in review for metastatic breast cancer at SABCS23 was one of the best overviews I have seen. I know I am biased, but it was truly outstanding.”
Rebecca Shatsky (USA)
“So incredibly proud of my mentee Hemali Sharma for getting a GRASP patient advocacy award on our poster “Genomic Landscape and Clinical Outcomes of Triple-Negative Invasive Lobular Carcinoma” at SABCS 2023! Hemali is an incredible 3rd year breast oncology fellow who has been working with me since the beginning of her internship at University of California San Diego!”
Tatiana Prowell (USA)
“One of my heroes Terlisa Sheppard was diagnosed with stage 3 estrogen receptor +, HER2+ breast cancer while pregnant in ‘98. When I met her around 6 years ago at an advocacy session, she’d had Metastatic Breast Cancer for years and had brain metastasis. Today she liked my tweet. Medicine is the best job. Science will win.
Read Terlisa’s inspiring story here and remember that this is why we do it, oncology twitter. Wherever you live or work in the oncology ecosystem, your effort is what makes this possible. Believe!”
Fumiko Ladd Chino (USA)
“It is not ‘one size fits all’ for breast cancer treatment or for financial assistance. This all speaks to the larger issue… we need to do better about improving meaningful assistance during treatment [and] also through survivorship”
Read more here.
Elisa Agostinetto (Belgium)
“What a SABCS23!
- My first oral presentation on the SABCS San Antonio stage.
- The results of our global academic effort presented in the General Session and published on JAMA.
- New data with high impact for breast cancer patients to
Love to all colleagues and friends who make this possible.”
Amy Comander (USA)
“It was wonderful to spend time this afternoon with Laura Carfang and her incredible team at Surviving Breast Cancer! It is an honor to serve as a medical advisor for this great organization which is dedicated to educational initiatives and improving the lives of individuals with breast cancer.”
Chiara Corti (USA)
“Such a pleasure talking with many of you today! Oncologists, advocates, pathologists, health economics experts, and also PhD students had truly insightful questions and interesting suggestions. Thanks to you all for spending some time with me!”
Michelle Li (Australia)
“From a breast fellow perspective, there is so much value in the SABCS23 clinical case discussion session. Hearing different perspectives from leading experts around the world is invaluable – also shows the many nuances behind the tricky cases we see in our clinics.”
Paolo Tarantino (USA)
“The largest multi-omic characterization of male breast cancers to date (n=137, compared with 10k female breast cancers) is presented at SABCS23 by Dario Trapani.”
Anne Marie Mercurio (USA)
“A personal highlight of SABCS23 – seeing Stephanie Graff at the Dr. Love Foundation table. My first baby steps into advocacy were beside Dr. Love who was always gracious with her time and was so accepting of patient advocates.”
Stacey Tinianov (USA)
“We are here at SABCS23 poster session three! Stop by Row 28- Poster 1 to learn about “More Than a Diagnosis: An Untold Story of Quality of Life” by Advocates for Collaborative Education (ACE).”
Antonio Giordano (USA)
“A frequent alteration in breast cancer. Difficult to tackle. We present data of FUTIBATINIB (FGFR inhibitor) in a cohort of TNBC with FGFR2 amplification. So much work to identify the responders: FGFR often not a driver oncogene.”
Amol Akhade (India)
“Slide of the day for me by Reshma Jagsi. Headlines can Harm. Let’s be responsible in interpretation. This is true not only for radiotherapy but also for “Headline hype” for new drugs.”
“Absolutely thrilled to have this work presented at SABCS2023 and now published in Journal of the National Cancer Institute (JNCI). Grateful for the collaboration with amazing co-authors and indebted to Sumanta K. Pal for his advice “do not give up”. Full text here.”
Sara Tolaney (USA)
“INAVO120: Fulvestrant + Palbociclib +/- Inavolisib in Hormone Receptor +/- metastatic breast cancer (mBC) with relapse on or w/i 1 yr of adj essential thrombocythaemia (ET) leading to impressive data Progression Free Survival: 15.0 vs 7.2 months HR 0.43 , p<0.0001 Overall Survival trend HR 0.64 58.6% hyperglycemia (5.6% g3-4) 51.2% stomatitis (5.6% g3-4) 25.3% rash (g3-4).”
Jame Abraham (USA)
“Currently 75% of Artificial Intelligence applications are in pathology and radiology- among cancers, breast cancer leads the pack – it will be exciting to watch the evolution of AI in the next 5 years.”
Margaret Gatti-Mays (USA)
“Updated Event-free survival (EFS) from KN522 by Peter Schmid shows lower distant recurrence risk in patients with pCR who received chemo-IO but no difference in incidence of brain metastasis. Interesting since generally increases systemic control equals decrease of CNS disease.”
Vivek Subbiah (USA)
“Press release SABCS23: Roche announces positive Phase III results for inavolisib combination in people with advanced hormone receptor-positive, HER2-negative breast cancer with a PIK3CA mutation.”
Read more here.
“Thank you to all the in-person and online participants for making SABCS23 a tremendous success. With well over 12,000 tweets and nearly 94 million impressions on X/Twitter, we thank those who joined in the conversation on social media.”
